SCHEMBL2316643

SCHEMBL2316643

CC(C)(NC(=O)CCc1ccccc1)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLTP P55058 5/20 0.56
RORC P51449 2/20 0.53
ALDH1A1 P00352 2/20 0.50
DGAT1 O75907 1/20 0.49
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 1/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
MAOB P27338 1/20 0.43
ADORA2B P29275 1/20 0.43
XIAP P98170 1/20 0.42
LMNA P02545 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2316445 0.84 RORC (0.51) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2315053 0.84 RORC (0.49) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2318702 0.83 RORC (0.54) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2315021 0.83 RORC (0.58) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2316382 0.82 RORC (0.58) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2485677 0.82 PLTP (0.51) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2316532 0.82 RORC (0.49) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2313541 0.81 RORC (0.51) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL2316628 0.81 RORC (0.48) PLTPRORCALDH1A1DGAT1HPGD
SCHEMBL28792682 0.81 ALDH1A1 (0.49) PLTPRORCALDH1A1DGAT1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 PLTP 575/4885RORC 1166/4885ALDH1A1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.